Skip to main
MBOT
MBOT logo

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc. has demonstrated positive preclinical results that have advanced its LIBERTY® Robotic Surgical System into human trials, showcasing a notable 95% success rate in targeting specific vascular areas during catheterizations. The company has submitted an Investigational Device Exemption (IDE) application to the FDA, reflecting confidence in its technology and its potential to innovate within the surgical landscape. Additionally, with all six LIBERTY systems achieving 100% usability and technical success in studies, Microbot Medical is well-positioned to improve surgical outcomes and gain competitive advantages through its strong patent portfolio.

Bears say

Microbot Medical Inc faces significant operational and financial uncertainties, primarily stemming from its reliance on the successful clinical trials and regulatory approval of its flagship product, LIBERTY. The company reported a net loss of $10.7 million, equating to a loss of $1.05 per share, which underscores the financial challenges it encounters as it seeks to commercialize its technologies. Additionally, risks associated with establishing partnerships for market penetration and the potential for dilution further contribute to a negative outlook on the firm's financial stability and growth prospects.

Microbot Medical (MBOT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.